Hybridoma cell lines are used to produce monoclonal antibodies for a wide range of applications in research and therapeutics. Hybridomas are created by fusing two different cell types: B lymphocytes (which produce antibodies) and myeloma cells (which can divide indefinitely). The resulting hybrid cell type, called a hybridoma, possesses the ability to produce large quantities of a single monoclonal antibody.

However, hybridoma development is a very time-consuming and labor-intensive process, with a very low success rate. Only a small percentage of B lymphocytes will successfully fuse with the myeloma cells and produce viable hybridomas, with a fraction of those producing high titers of the desired antibody. Large numbers of newly created hybridoma cell lines will need to be screened to identify the ones suitable for further development and use.

Despite the challenges and lower success rate, the hybridoma process remains a valuable tool toproduce monoclonal antibodies. With proper planning, optimization and processes, hybridomas can yield high-quality and specific monoclonal antibodies.

Our Danaher Life Sciences companies provide a wide range of solutions & fit-for-purpose technologies for partial or end-to-end hybridoma workstations for the development and screening of hybridoma cells.